WY-46824 is a norepinephrine-dopamine reuptake inhibitor related to venlafaxine that was disclosed by Paige Mahaney, et al. of Wyeth in 2008. The compound actually appears in an article a year earlier in 2007 but is not the main focus of the work. It has NET binding of 46 nM, DAT = 58 nM and SERT = 18795 nM. The racemic compound was resolved into its constituent enantiomers, and the (S) enantiomer is the more active one. The N-desmethyl derivative shows similar activity.
Property | Value |
---|---|
dbo:abstract |
|
dbo:casNumber |
|
dbo:chEMBL |
|
dbo:fdaUniiCode |
|
dbo:pubchem |
|
dbo:thumbnail | |
dbo:wikiPageID |
|
dbo:wikiPageLength |
|
dbo:wikiPageRevisionID |
|
dbo:wikiPageWikiLink | |
dbp:c |
|
dbp:casNumber |
|
dbp:chembl |
|
dbp:chemspiderid |
|
dbp:cl |
|
dbp:h |
|
dbp:iupacName |
|
dbp:n |
|
dbp:o |
|
dbp:pubchem |
|
dbp:smiles |
|
dbp:stdinchi |
|
dbp:stdinchikey |
|
dbp:unii |
|
dbp:width |
|
dbp:wikiPageUsesTemplate | |
dcterms:subject | |
gold:hypernym | |
rdf:type |
|
rdfs:comment |
|
rdfs:label |
|
owl:sameAs | |
prov:wasDerivedFrom | |
foaf:depiction | |
foaf:isPrimaryTopicOf | |
is dbo:wikiPageRedirects of | |
is dbo:wikiPageWikiLink of | |
is foaf:primaryTopic of |